The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLI.a

Pulmonary edema, noncardiogenic (NCPE)

Publications

Michaelson J

Thiazolidinedione associated volume overload and pulmonary hypertension.

Therapeutic advances in cardiovascular disease 2008 Dec;2;435-8 — 2008 Dec — 435-8

Cekmen N, Cesur M, Cetinbas R, Bedel P, Erdemli O

Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.

Journal of intensive care medicine 2006 Jan-Feb;21;47-50 — 2006 Jan-Feb — 47-50

Fonarow GC

Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.

American heart journal 2004 Oct;148;551-8 — 2004 Oct — 551-8

Kermani A, Garg A

Thiazolidinedione-associated congestive heart failure and pulmonary edema.

Mayo Clinic proceedings 2003 Sep;78;1088-91 — 2003 Sep — 1088-91

Idris I, Gray S, Donnelly R

Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability.

Diabetologia 2003 Feb;46;288-90 — 2003 Feb — 288-90

Wang F, Aleksunes LM, Reagan LA, Vergara CM

Management of rosiglitazone-induced edema: two case reports and a review of the literature.

Diabetes technology & therapeutics 2002;4;505-14 — 2002 — 505-14